tbuckley/cabot-search huggingface dataset:
Abstract 20090: Transcatheter Patent Foramen Ovale Closure to Reduce Headache Burden in Patients with Migraine Headaches
Authors: John F Rhodes, Amanda S Green, Kevin D Hill
Journal: Circulation (2010)

Background:  Patients (pts) that suffer from migraine headache (MH) often are moderate-severely disabled and have failed multiple therapies. In addition, a coexistent patent foramen ovale (PFO) is common and many pts have suffered a paradoxical cerebrovascular accident (CVA) or transient ischemic attack (TIA). We retrospectively reviewed our experience regarding PFO closure for these pts to assess the affect on headache burden.   Methods:  Data for pts with MH that underwent PFO closure between January 2003 and January 2010 were reviewed. Inclusion required MH diagnosed by a neurologist, a 3-month headache burden by MIDAS (Migraine Disability Assessment) of Grade II to IV (mild-severe disability), a reported history of a least 3 failed MH treatments, and a right to left shunting PFO. The cohort was divided into three groups. The first group (MH-CVA) included pts with MH and a CVA, the second group (MH-TIA) included pts with MH and a TIA, and the third group (MH-alone) included pts with only MH. Procedures for PFO closure were performed using standard technique. All records were reviewed for procedural outcome, late adverse events, and headache burden.   Results:  Our cohort included 84 pts with 28 MH-CVA, 30 MH-TIA, and 26 MH-alone. Median age was 34yrs (range: 17→47) and the mean balloon stop-flow diameter was 9±3mm (range: 5–18). Mean procedure and fluoroscopy times were 42±12min and 8±5min, respectively. There were no procedure-related adverse events. Overall, 6/84 pts (7.1%) had a residual leak at the 6 month follow-up with 3 pts returning for successful second occluder device placement. With an overall median follow-up of 32 months (range 5–76) there have been 5 pts with a non-focal event and 2 pts with atrial arrhythmia. Overall the mean MIDAS grade decreased significantly from 27.5±7.7 at baseline versus 2.7±3.4 at latest follow up, (p   Conclusions:  These data indicate that device PFO closure is safe and effective in treating MH pts with a significant decrease in headache burden. This therapy should be considered an alternate when pharmacologic therapies have failed.
A Retrospective Study Of The Use Of Partially-Covered And Uncovered Self-Expandable Metallic Stent For Management Of Airway Complications In Lung Transplant Recipients.
Authors: Vi Doan, Benjamin Bondue, Guy Vandermoten, Benoît Rondelet, Youri Sokolow, Maria Jose Ruiz Patino, Christiane Knoop, Matteo Cappello, Paul De Vuyst, Dimitri Leduc
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
Abstract 1463: Titin Isoform Phosphorylation in Failing Human Myocardium
Authors: Attila Borbely, Nazha Hamdani, Ines Falcao-Pires, Istvan Edes, Adelino F Leite-Moreira, Ger J Stienen, Jolanda van der Velden, Walter J Paulus
Journal: Circulation (2007)

Titin lowers myocardial diastolic stiffness by shifting its isoform expression from the stiff N2B to the compliant N2BA isoform and by increasing its phosphorylation. Resting tension (RT) of cardio...
Occupational Hazards in the Health Professions
Authors: Dag K. Brune, Christer Edling
Journal: Annals of Internal Medicine (1990)

General Concepts. Occupational Injuries and Diseases. Indoor Climate. Human Immunodeficiency Virus (HIV). Microbiological Hazards. Anesthetic Gases. Antineoplastic Agents. Methyl Methacrylate. Histopathological Laboratories. Radiation Hazards. Biomechanical Aspects of Bodyloading During Work and Sport. Ergonomics for Health Professionals in Hospitals and the Community. Eczema. Hazards in the Dental Environment -Curing Lights and High-Speed Handpieces. Effects of Vibration in the Hands. Mercury in Dentistry. Risks and Prevention of Musculoskeletal Disorders Among Dentists. Dental Laboratories. The Psychosocial Working Environment. Index.
Regional Anatomy Illustrated
Authors: J. W. Smith
Journal: BMJ (1946)

than an explicit step-by-step 'how to do it' account.On the other hand, the chapter on some applications of stereological methods to studies of the anatomy of various organs allows a very clear view of the experimental approach and methods of the authors and their colleagues, especially as they are applied to light microscope studies.(Their studies are based mainly on paraffin or semithin resin sections.)Including as they do the computer programs (in FORTRAN IV) relating to their own research, the authors' accounts give valuable insight into the methods of work of a well known and respected American school of study in quantitative histology.Taken together, the accounts demonstrate well the possibilities that the approach of stereo- logical morphometry offers to anatomists.This book, though not perhaps the ideal starting point for students commencing bench work, is easy and enjoyable to read and, despite a price of around £40, will be read, if not by the students, by many of their teachers.M. A.
Immunogenetic Studies on X-Irradiated Mice Treated with Homologous Hematopoietic Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Michael Feldman, David Yaffe
Journal: JNCI Journal of the National Cancer Institute (1958)

An analysis was made of the immune reactions taking place in X-irradiated mice treated with homologous hematopoietic cells. The results of experiments with hybrid combinations of hosts and donors suggest that the grafted cells react immunologically against the isoantigens of the irradiated recipient. The production of anti-C3H agglutinins by the inoculated C57BL cells was demonstrated by the transfer of lymph nodes from the irradiated and treated C3H mice back to normal C57BL mice. The “cytotoxic” anti-host immune reaction responsible for the lethal “secondary disease” of homologously treated mice was demonstrated by the passive transfer of transplantation immunity produced by the isoantigens of the recipient. Bone marrow from irradiated C3H mice treated with C57BL cells conferred on other irradiated C3H mice a much shorter survival time than normal C57BL cells. It is concluded that the cells from the C57BL-treated C3H donors were immunologically activated by the primary C3H hosts and killed the secondary C3H hosts through an immunologically secondary response. The mortality of mice treated with mixed embryonic isologous and adult homologous cells indicates that even if, theoretically, a delayed antigraft response is feasible, the graft antihost response has a dominant role in the immunogenetic incompatibility. An attempt to overcome this incompatibility was made by injecting irradiated C3H mice with fetal C57BL liver cells. The increased survival time obtained in this experiment may suggest a method for the application of the principles of biological protection to animals of genetically heterogeneous populations.
Studies in Rickets
Authors: H. J. Gerstenberger, J. I. Hartman, John D. Nourse, Norman C. Wetzel, D. N. Smith
Journal: Annals of Internal Medicine (1927)

Article1 November 1927Studies in RicketsH. J. GERSTENBERGER, M.D., J. I. HARTMAN, M.D., JOHN D. NOURSE, M.D., NORMAN C. WETZEL, M.D., D. N. SMITH, B.S.H. J. GERSTENBERGER, M.D.Search for more papers by this author, J. I. HARTMAN, M.D.Search for more papers by this author, JOHN D. NOURSE, M.D.Search for more papers by this author, NORMAN C. WETZEL, M.D.Search for more papers by this author, D. N. SMITH, B.S.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-5-305 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptInstead of attempting to go into detail concerning the etiology, pathogenesis, pathology, symptomatology, prognosis, treatment and prophylaxis of rickets, I prefer to use this opportunity to acquaint you with some of the work which has been done at the Babies and Childrens Hospital by Drs. Nourse, Hartman, Wetzel and myself, in connection with human rickets.Let me indicate too, that while progress has been made in the accumulation of knowledge concerning the etiology and treatment of rickets, but little has been accomplished in fathoming the pathogenesis of this disease. However, some progress also has been made in this direction. It... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cleveland, Ohio*Presented to the American College of Physicians, Cleveland, Ohio, February 24, 1927. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Bedeutung der Vitaminlehre mit besonderer Berücksichtigung der KinderheilkundeVitamine der MilchDie Behandlung und Verhütung der Rachitis und Tetanie 1 November 1927Volume 1, Issue 5Page: 305-309KeywordsChildrenEtiologyPathogenesisProphylaxis Issue Published: 1 November 1927 PDF downloadLoading ...
Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation
Authors: David R. Holmes, Shephal K. Doshi, Saibal Kar, Matthew J. Price, Jose M. Sanchez, Horst Sievert, Miguel Valderrabano, Vivek Y. Reddy
Journal: Journal of the American College of Cardiology (2015)
Breakfast of Champions or of Hypertensives?
Authors: Pedersen Tr
Journal: New England Journal of Medicine (1986)

The original Norwegian Multicenter Study on Timolol after Myocardial Infarction was a double-blind, randomized study comparing the effect of timolol with that of placebo for up to 33 months after acute myocardial infarction. The initial results showed that the cumulated mortality rate was 39.4 per cent lower among 945 patients randomly assigned to timolol treatment than among 939 patients randomly assigned to placebo (P = 0.0003). After the end of the double-blind period the majority of participating patients in the timolol group continued to receive beta-adrenergic blockade, whereas the majority of placebo-treated patients continued without such blockade. During an extended follow-up of participating patients up to 72 months after randomization, the mortality curves of the two groups continued to rise in parallel. Cumulated mortality rates were 32.3 per cent in the placebo group and 26.4 per cent in the timolol group (P = 0.0028). We conclude that the previously observed early beneficial effect of beta-adrenergic blocking therapy is maintained for at least six years after infarction.
The dose-response relation is probably linear
Authors: D. F Marks
Journal: BMJ (1995)

EDITOR,—Richard Doll and colleagues claim a U shaped dose-response curve for mortality and alcohol.1 If valid, their observations have profound implications for health education. Their findings are being widely interpreted as proving that drinking a few drinks every day leads to a longer life than drinking no alcohol at all. Regrettably, the infelicitous design of their questionnaire means that the reported findings are invalid and the conclusions potentially seriously misleading. The questionnaire was faulty in at least three ways: it failed to differentiate subjects who had never been drinkers from former …
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer - preliminary report
Authors: Y. Chao, C. P. Li, T. Y. Chao, W. C. Su, R. K. Hsieh, M. F. Wu, K. H. Yeh, L. T. Chen, A. L. Cheng
Journal: Journal of Clinical Oncology (2005)

4156 Background: To evaluate the response rate and safety of weekly paclitaxel (Taxol) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1:4 molar ratio) and leucovorin in patients with advanced gastric cancer. Methods: Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-hour infusion at a dose of 100 mg/m2 on days 1 and 8, and oral UFT 300 mg/m2/d plus leucovorin 90 mg/d were given starting from day 1 for 14 days, followed by a 7-day period without treatment, treatment repeated every 21 days. Results: From February 2003 to August 2004, 36 patients were enrolled. The median age was 60.8 years (range: 32 to 82). Among the 33 patients evaluable for tumor response, 1 achieved complete response and 12 partial response, with an overall response rate of 39.4% (95% CI: 11.2% to 53.0%). All 36 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.1 months and 7.7 months, respectively. Major grade 3–4 toxicities were neutropenia in 15 patients (41.7%) and diarrhea in 7 patients (19.4%). Treatment was discontinued due to treatment-related toxicities in 2 patients (5.6%). No patient died of treatment-related toxicities. Conclusions: We conclude that this paclitaxel-containing regimen is effective and well tolerated in the treatment of advanced gastric cancer. No significant financial relationships to disclose.
OBSERVATIONS ON THE USE OF FLUIDS AND LUMBAR PUNCTURE IN THE TREATMENT OF DELIRIUM TREMENS
Authors: Jackson M. Thomas, Elvin V. Semrad, Robert S. Schwab
Journal: Annals of Internal Medicine (1939)

ExcerptIn 1915 Steinebach,1 reported that he observed remarkable improvement in 18 cases of delirium tremens immediately after lumbar puncture and withdrawal of cerebrospinal fluid. He thought that improvement resulted from the reduction of a high cerebrospinal pressure and a diminution of "toxic" elements circulating in the cerebrospinal fluid. Since Steinebach's first report appeared, the literature pertaining to the treatment of delirium tremens has contained other citations of the therapeutic efficacy of lumbar puncture in the treatment of this disorder (Hoppe,2 Goldsmith,3 and Ebaugh and Johnson4).Assuming that an increase in cerebrospinal fluid pressure and edema play a significant rôle in...
The Pocket Formulary for the Treatment of Diseases in Children.
Authors: Ludwig Freyberger
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P401: Time Trend of Cardiovascular Diseases Prevalence in The Italian Adult Population: The Italian Health Examination Survey
Authors: Chiara Donfrancesco, Luigi Palmieri, Francesco Dima, Cinzia Lo Noce, Patrizia De Sanctis Caiola, Serena Vannucchi, Diego Vanuzzo, Simona Giampaoli
Journal: Circulation (2012)

Background: Despite cardiovascular diseases (CVD) are the leading causes of death and hospitalization in nearly all countries in Europe, there are paucity, weak quality and comparability of data. The periodic Health Examination Survey (HES) represents in Italy the major source of information on CVD at national level thanks to the adoption of standardized methodologies throughout the country. The aim is to present differences in trends of CVD prevalence by gender in the Italian adult population from 1998 to 2008. Methods: Randomized population samples stratified by age and sex were examined. In 1998, 9,712 men and women aged 35–74 years were enrolled in all Italian regions; ongoing screening started in 2008 is enrolling 9,020 persons. A standardized questionnaire investigates cardiovascular disease and pharmacological treatments. The anamnesis is positive when clinical diagnosis has been made by a physician. Electrocardiograms read in Minnesota code are also performed and used to define previous myocardial infarction. Results: Data are from 12 regions in the North, Center, and South of Italy: 3,704 men and women in 1998 and 3,479 persons in 2008 are compared. In men, prevalence of cerebrovascular events decreases from 1.5% (95% confidence interval: 1.0-1.9%) in 1998 to 0.6 (0.3–0.9%) in 2008; in women, prevalence results stable: 0.9% in 1998 (0.5–1.3%) and 0.7% in 2008 (0.4–1.1%). Prevalence of myocardial infarction results stable both in men and women: in 1998, 1.9% in men (1.4–2.4%) and 0.6% in women (0.3–0.9%), and in 2008, 2.0% (1.4-2.7%) and 0.6% (0.3-0.9%) respectively; angina pectoris results stable as well: in 1998, 2.2% in men (1.7-2.8%) and 3.9% in women (3.1-4.6%), and in 2008, 3.2% (2.5-4.0%) and 4.5% (3.6-5.4%) respectively. Prevalence of by-pass or angioplasty surgery increases in men: 2.4% (1.8-3.0%) in 1998, and 4.5% (3.6-5.4%) in 2008; in women increasing is not significant: from 0.2% (0.0-0.4%) in 1998 to 0.7% (0.3-1.1%) in 2008. Stratifying data by geographical area (North, Center, South and Island) all comparisons become not significant; in men only, cerebrovascular decreasing and by-pass or angioplasty surgery increasing trends tend to be confirmed in all three areas. Conclusions: Trends between 1998 and 2008 decrease in cerebrovascular events and increase in prevalence of by-pass or angioplasty surgery, especially in men. Stable prevalence resulted for myocardial infarction and angina pectoris. Cerebrovascular decreasing trend is in line with smoking prevalence and mean of blood pressure decreasing in the country. Further analyses considering data from all Italian regions are needed to confirm results.
Medical Electronics in Cardiovascular Disease.
Authors: Charles Kaye Friedberg
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer.
Authors: S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song, T. Zhang, J. Baselga
Journal: Journal of Clinical Oncology (2011)

TPS110 Background: Activation of the PI3K/AKT/mTOR pathway is common in breast cancer. Preclinical studies indicate that the dual inhibition of IGFR and mTOR may be additive or synergistic and abrogates the feedback activation of AKT due to rapamycin analog mTOR inhibitors. A phase I study of the mTOR inhibitor RIDA and the anti-IGFR antibody DALO demonstrated that the combination was feasible and well-tolerated at doses that were nearly those used for the two single agents and with dose limiting toxicity of stomatitis, similar to RIDA as monotherapy. A preliminary signal of anti-tumor activity, including partial responses and prolonged progression free survival, was observed in ER+ breast cancer, especially in high proliferation tumors. This observation is supported by data from tumor profiling and pre-clinical data suggesting that ER+ high proliferation breast cancer may be responsive to the RIDA-DALO combination. Methods: This is a two-part, adaptive design study intended to first test the combination of RIDA-DALO against a standard agent, exemestane, for ER+ positive breast cancer that has progressed after aromatase inhibitors. The trial is a multi-center, international, randomized study with PFS as the primary endpoint. Patients (pts) are stratified into high and low proliferation strata based on baseline Ki67, and the low proliferation stratum is capped to ensure adequate enrollment of high proliferation pts. If Part A shows a PFS benefit for RIDA-DALO, Part B is intended to show the PFS benefit of the combination over the single agents by comparing RIDA-DALO to RIDA and DALO. Part B will be further adapted based on whether the PFS benefit in Part A is observed in all-comers or the high proliferation subset. Tumor tissue is collected for molecular profiling and analysis of intrinsic subtype, with an efficacy analysis based on classification of tumors using the genomic grade index (GGI) as an exploratory objective. This trial design is intended to establish proof of concept that RIDA-DALO can prolong PFS in ER+ breast cancer in all-comers or a high proliferation subset by Ki67, while efficiently addressing the development of two investigational agents in combination and leading to a two-arm phase III design.